News

Get Help if You Lost Money in Sangamo Therapeutics (SGMO)

Get Help if You Lost Money in Sangamo Therapeutics (SGMO)

Understanding Sangamo Therapeutics and Investment Risks

Sangamo Therapeutics, Inc. is a leading biotechnology company focused on genetic medicine. Recently, concerns have surfaced about potential investment losses following critical announcements that have shaken investor confidence. The company primarily engages in the development of innovative therapies based on gene editing and gene therapy technologies.

Recent Developments and Impact on Investors

Investors of Sangamo Therapeutics experienced significant turmoil following the announcement of a partnership termination with Pfizer Inc. This pivotal moment occurred after the market closed on December 30, 2024, and dealt a severe blow to investor expectations.

The abrupt end of this collaboration stirred worries about the company's future projects, particularly its hemophilia A gene therapy candidate. Consequently, on December 31, 2024, Sangamo's stock faced a steep decline of $1.32, translating to a staggering 56.4% drop in value, which closed at just $1.02 per share. Such drastic fluctuations prompt many to consider their legal options regarding securities fraud.

Seeking Recourse for Losses

If you find yourself among the investors who endured financial losses due to these developments, it is essential to evaluate your legal rights. Reputable law firms like the Law Offices of Howard G. Smith are well-equipped to offer guidance on pursuing potential claims. Understanding your rights and options may be crucial in recovering lost investments.

Importance of Legal Representation

Legal representation plays a multifaceted role in assisting affected investors. Experienced firms can help identify whether Sangamo's actions constituted any violations of federal securities laws and advise on joining potential class actions or filing individual claims. In the case of Sangamo Therapeutics, many questions linger about the corporate conduct leading up to the partnership's termination and its disclosure.

Who Should Contact Legal Experts?

Investors who purchased Sangamo securities and sustained losses should consider reaching out to legal experts. Whether you have information related to the company or simply seek clarity on your situation, obtaining legal advice is a step in the right direction.

What to Expect When Reaching Out

Contacting the Law Offices of Howard G. Smith for a consultation is an integral first step. They can offer insights into the potential legal avenues available to recoup losses arising from securities fraud. Make sure to have relevant documentation and personal records ready to facilitate thorough discussions with legal professionals.

Next Steps for Affected Investors

Investors should remain vigilant about their rights. If you are interested in pursuing claims to recover losses from the investment in Sangamo Therapeutics, do not hesitate to contact the Law Offices of Howard G. Smith. Based in Pennsylvania, the law firm provides avenues for investors to seek justice for losses incurred.

To reach them, you can use the following contact details. They are situated at 3070 Bristol Pike, Suite 112, and available via phone at (215) 638-4847. Additionally, emails can be sent to express your concerns.

Frequently Asked Questions

1. What triggered the drop in Sangamo's stock price?

The stock price fell after Sangamo disclosed the termination of its partnership with Pfizer for a gene therapy product, leading to a substantial loss in market value.

2. How can I determine if I have a case against Sangamo?

Review your investment history and consult with legal professionals to understand if the company's actions amounted to securities fraud.

3. What should I prepare when contacting a law firm?

Gather your investment records, communications related to your purchase, and any relevant documents to discuss your situation comprehensively.

4. Can I join a class action lawsuit?

If you meet certain criteria, joining a class action lawsuit against Sangamo might be possible. Your legal counsel can provide more details.

5. Is there a cost for the initial consultation?

Many law firms offer free initial consultations to assess legal claims, enabling you to seek advice without upfront costs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AI Agents Race: 10M Downloads Spark Competitive Fire

Updated Category News Views 5

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

Continue Reading
IBM Backs Leena AI: Shaping Enterprise Automation

Updated Category News Views 10

IBM's Strategic Bet on Enterprise Automation Diving into the blazing 2026 market, IBM Ventures has thrown its weight behind Leena AI, an enterprise agentic AI firm that's out to shake things up. You see, the name of the game isn't just flashy AI chatbots anymore. Companies like Leena AI are setting their sights on the back-office grunt work—the lifeblood operations in...

Continue Reading
SQUID Platforms on CDAO Tradewinds Marketplace

Updated Category News Views 6

Old School Meets New Tech: SQUID's 'Awardable' Moment In an era drowning in data, IESE Solutions throws us a lifeline with its SQUID platform—assessed 'Awardable' and now live on the Department of War's Chief Digital and Artificial Intelligence Office's (CDAO) Tradewinds Solutions Marketplace. Sounds technical, right? Well, let’s dive into why it matters for those...

Continue Reading
Top Gun F/A-18 Super Hornet Lands at Palm Springs

Updated Category News Views 0

Aviation Marvel Now Anchored at Palm Springs There's something electric about standing next to a piece of history, especially when it involves the thunderous scream of an F/A-18 Super Hornet. The Palm Springs Air Museum is pulling back the curtains on an experience that's got aviation buffs and Top Gun fans buzzing like bees. On November 7, 2026, this central hub of...

Continue Reading
Lincoln's Legal Tangle: Stock Plunge Sparks Lawsuit

Updated Category News Views 2

Lincoln Educational's Troubles Unravel You think you've seen it all, then boom—Lincoln Educational Services hit the skids with their stock diving close to 25% back in August 2026. This ain't your usual small hiccup; we’re talking a lawsuit filed and investors eyeing action as miserly as a broker when the market tumbles. News like this? It shakes the rafters of any...

Continue Reading
LAZ Parking and indiGOtech's Bold EV Charging Move

Updated Category News Views 8

EV Chargers: The Future Parked Closer? I've been around the block more times than a cabbie in Manhattan rush hour, and let me tell you, when it comes to EVs, folks are still playing catch-up. But here's a kicker—LAZ Parking and indiGOtech have decided they're not gonna wait around. This joint venture of theirs aims to sock some sense into the old condo complex parking...

Continue Reading
Sophont's Holon-S1: Revolutionizing Pathology and AI

Updated Category News Views 15

Pushing Boundaries in Tumor Analysis with AI In the world of medical AI, it's not every day you hear about a tool that claims to read the secrets hidden within routine pathology slides to predict tumor behavior. Yet, here we are with Sophont's latest brainchild, the Holon-S1. This thing is more than just another AI model; it's a giant leap towards pulling the veil off...

Continue Reading
MEDITECH and Lifemed AI Join Forces on Healthcare AI

Updated Category News Views 4

Lifemed AI and MEDITECH: A New Chapter in Healthcare You’d think by now the healthcare systems would be catching a break with technology, but here comes another twist. Lifemed AI and MEDITECH have banded together to tackle the notorious issue of claim denials head-on. Picture this: billions squandered every year because of avoidable administrative slip-ups. That's money...

Continue Reading
Hyliion Partnership Woes: Investors Eye Legal Options

Updated Category News Views 4

Hyliion's Rocky Partnership Sparks Market Concern If you've got your cash tied up in Hyliion Holdings Corp. (NYSE: HYLN), you've probably got an eye twitch by now. Last June, a damning report from Pelican Way Research threw a wrench in Hyliion's plans with VFG Holdings, calling into question the whole commercial rationale of their newest partnership. Imagine staking $133...

Continue Reading
Security Leadership Faces Unseen Identity Risks

Updated Category News Views 10

Rocky Road in Identity Security Catch this: you're a security honcho, thinking you've forked over enough dough to lock down human and machine identities. But now, it turns out, most of your kind still don't have a full handle on who or what is poking around your systems. Talk about a wrench in the gears. This latest report from Oak drags the reality into the limelight:...

Continue Reading

Top 5 Most Recently Viewed Articles

Editas Medicine Set to Present at the ESGCT Annual Congress

Updated Category News Views 182

Editas Medicine's Upcoming Presentation Highlights Editas Medicine, Inc. (NASDAQ: EDIT), a trailblazer in gene editing, is excited to announce that it will present at the renowned European Society of Gene and Cell Therapy (ESGCT) Congress. The congress is set to occur from October 7 to October 10, making this a significant occasion for the company and the field of gene...

Continue Reading
Innovative Solutions for Medical Devices: ICP DAS-BMP at COMPAMED

Updated Category News Views 193

ICP DAS-BMP Showcases Medical Innovations at COMPAMED ICP DAS-BMP, a prominent manufacturer from Taiwan, is gearing up for the prestigious COMPAMED event taking place in Germany. This event, which draws significant attention from the medical device industry, showcases advancements in medical-grade thermoplastic polyurethane (TPU) materials. Focus on Low-Migration and...

Continue Reading
Broadcom's Performance and ETF Options for Investors

Updated Category News Views 217

Broadcom's Recent Performance and Growth Potential Broadcom Inc. has made headlines recently with its remarkable performance in the tech sector. Following a solid earnings report for the second quarter, this semiconductor leader has seen its stock, designated as AVGO, score a notable jump of nearly 19% year-to-date. This surge has been particularly impressive, as the...

Continue Reading
InCarda Therapeutics Welcomes Dr. Myles Greenberg as CEO

Updated Category News Views 236

InCarda Therapeutics Welcomes Dr. Myles Greenberg as CEO InCarda Therapeutics, a clinical-stage biopharmaceutical firm dedicated to developing cutting-edge treatments for cardiac arrhythmias, has appointed Dr. Myles Greenberg, MD, MBA, as its new Chief Executive Officer. Dr. Greenberg is set to lead the company as they work on their flagship product, an orally inhaled...

Continue Reading
Jim Cramer's Insight: A Tipping Point for Nvidia's Stock

Updated Category News Views 148

Understanding Jim Cramer's Perspective on Nvidia CNBC’s Jim Cramer hinted at a potential turning point for NVIDIA Corp. (NASDAQ: NVDA) after the stock reached $127. This could signal a bottom for the semiconductor giant after its recent setbacks. Market Dynamics: What Cramer Noted Cramer’s Observations According to Cramer, the $127 mark could indicate a pivotal moment...

Continue Reading